How to Get Vyvanse in Arkansas: Prescriptions, Telehealth, and Pharmacies

What Is Vyvanse and Who Can Prescribe It in Arkansas?

Vyvanse is the brand name for lisdexamfetamine dimesylate, a prodrug that converts to active d-amphetamine after oral ingestion. The FDA approved it for ADHD in 2007 and for moderate-to-severe binge eating disorder (BED) in 2015. Because lisdexamfetamine is a Schedule II controlled substance under federal law, obtaining it requires a written or electronic prescription from a DEA-registered prescriber. No refills are permitted on a single Schedule II prescription in Arkansas.

Who holds prescribing authority in Arkansas?

Three license categories can legally prescribe Vyvanse in Arkansas:

• Medical doctors (MD) and doctors of osteopathic medicine (DO): Full independent prescribing authority, including Schedule II controlled substances, with no additional collaborative agreement required.
• Nurse practitioners (APRN/NP): Arkansas APRNs must hold a current DEA registration and a valid collaborative practice agreement with a supervising physician to prescribe Schedule II medications. The Arkansas State Board of Nursing governs these requirements.
• Physician assistants (PA): PAs may prescribe Schedule II substances in Arkansas under a physician supervision agreement. The Arkansas State Medical Board oversees PA licensure.

A psychiatrist is not strictly required. Many family medicine physicians and internal medicine doctors in Arkansas prescribe Vyvanse for adults, and some pediatricians prescribe it for children aged 6 and older, consistent with the FDA label.

What the FDA label says about dosing

The Vyvanse prescribing information specifies a starting dose of 30 mg once in the morning for both ADHD and BED indications. Titration occurs in 10 mg or 20 mg weekly increments to a maximum of 70 mg per day. Evening doses are not recommended because of insomnia risk. Capsules may be opened and dissolved in water for patients who cannot swallow whole capsules.

Getting a Vyvanse Prescription in Arkansas: Step by Step

Obtaining your first Vyvanse prescription involves several concrete steps. Most patients complete the process in two to four weeks from initial contact to first fill, though insurance PA processes can extend that timeline.

Step 1: Schedule an evaluation

Contact a psychiatrist, your primary care physician, or a telehealth platform licensed in Arkansas. Ask specifically whether the provider is DEA-registered and comfortable prescribing Schedule II stimulants. Not every telehealth service prescribes controlled substances; confirm this before booking.

During the evaluation you will complete a clinical interview covering symptom history, prior medication trials, family history, cardiovascular history, and any substance use history. Most clinicians also administer a standardized rating scale such as the Adult ADHD Self-Report Scale (ASRS) or the Conners' Adult ADHD Rating Scales.

Step 2: Baseline assessments and labs

No single laboratory panel is universally mandated before starting Vyvanse, but Arkansas clinicians following standard of care typically order:

• Blood pressure and heart rate measurement (stimulants increase both)
• Baseline weight and BMI (relevant for BED indication and for pediatric growth monitoring)
• ECG if the patient has a personal or family history of cardiac arrhythmia, structural heart disease, or sudden unexplained death in a first-degree relative
• Thyroid function (TSH) when symptoms could indicate hyperthyroidism rather than ADHD
• Urine drug screen at baseline, required by many Arkansas prescribers before initiating a Schedule II controlled substance

No specific bloodwork is required by Arkansas statute before prescribing lisdexamfetamine, but individual practice policies and insurance plans may impose their own requirements.

Step 3: The prescription itself

Arkansas follows the federal DEA Electronic Prescriptions for Controlled Substances (EPCS) framework. Prescribers may send a Schedule II prescription electronically to a pharmacy, print a paper prescription on tamper-resistant stock, or, in some circumstances, phone in an emergency 72-hour supply with a written follow-up. Fax-only transmission is no longer standard practice for Schedule II drugs.

Schedule II prescriptions in Arkansas cannot be refilled. Your prescriber must issue a new prescription each time, typically for a 30-day supply. Some prescribers will post-date two or three prescriptions at once; Arkansas law permits this with the notation that each is not to be filled before a specified date.

Telehealth Prescribing for Vyvanse in Arkansas

Arkansas law permits telehealth prescribing of controlled substances for established patients, provided the prescriber holds a valid Arkansas medical license and a DEA registration that covers Arkansas. Prescribers who only hold an out-of-state license cannot legally prescribe to Arkansas residents.

The federal prescribing framework after the COVID-19 public health emergency

During the COVID-19 public health emergency, the DEA allowed prescribers to initiate Schedule II controlled substance prescriptions via audio-video telehealth without a prior in-person visit. The DEA has extended telemedicine flexibilities multiple times since the PHE ended; current guidance from the DEA should be confirmed by your provider at the time of your appointment, as rules may change.

What telehealth platforms operate in Arkansas?

Several national telehealth platforms list Arkansas as a covered state for ADHD evaluation. When comparing services, ask three questions before booking:

1. Is the prescriber licensed in Arkansas and DEA-registered?
2. Does the platform prescribe Schedule II stimulants, or does it limit controlled-substance prescribing to non-stimulant alternatives?
3. How are follow-up prescriptions handled given the no-refill rule on Schedule II drugs?

A practical decision framework for choosing between telehealth and in-person care in Arkansas:

| Situation | Recommended pathway | |---|---| | New ADHD diagnosis, no prior stimulant history, no cardiac risk factors | Telehealth evaluation is reasonable if DEA-registered provider is available | | Prior diagnosis with records from another state | Telehealth record review plus new Rx is common; confirm DEA registration | | Cardiac history, uncontrolled hypertension, or prior substance use disorder | In-person evaluation preferred; cardiologist clearance may be needed | | Child aged 6-12 | Pediatrician or child psychiatrist in-person visit strongly preferred | | BED indication | Telehealth evaluation reasonable; rule out anorexia or bulimia first |

Prior Authorization for Vyvanse in Arkansas

Prior authorization (PA) is the single biggest delay most Arkansas patients face. Both Arkansas Medicaid and many commercial plans require PA before covering Vyvanse.

Arkansas Medicaid (Arkansas DHS / Arkansas Total Care / Help Healthcare Solutions)

Arkansas Medicaid covers Vyvanse for ADHD and BED under a limited prior authorization policy. Common PA requirements include:

• Documentation of an ADHD or BED diagnosis using DSM-5 criteria
• Evidence of a trial of at least one preferred generic stimulant (typically generic mixed amphetamine salts or methylphenidate) that was ineffective or not tolerated
• Prescriber attestation that a brand-name formulation is medically necessary
• For BED: documentation that the patient has moderate-to-severe episodes per DSM-5 and that behavioral therapy alone was insufficient

PA approvals in Arkansas Medicaid are typically valid for 12 months and must be renewed annually. Denials may be appealed; your prescriber's office can submit supporting clinical notes.

Commercial insurance in Arkansas

Blue Cross and Blue Shield of Arkansas, QualChoice, and most large commercial plans treat Vyvanse as a non-preferred brand on Tier 3 or Tier 4. Step therapy (trying cheaper generics first) is common. If you have already tried and failed generic amphetamine salts, document that in writing before your PA submission.

Takeda's Vyvanse Savings Card is available for commercially insured patients and can reduce out-of-pocket costs to as low as $30 per month for eligible patients; it does not apply to Medicaid or Medicare.

Vyvanse Pharmacies in Arkansas

Retail pharmacy availability and the shortage

A national shortage of lisdexamfetamine has intermittently affected pharmacy stock since late 2022. Before sending your prescription to a specific pharmacy, call ahead to confirm stock. Independent pharmacies in smaller Arkansas cities (Fort Smith, Jonesboro, Fayetteville) may maintain better stock than large chains during shortage periods because they can order from multiple wholesalers.

Transferring a Vyvanse prescription from another state

Federal law classifies lisdexamfetamine as Schedule II, which prohibits prescription transfers between pharmacies. If you move to Arkansas or switch pharmacies, your prescriber must write a brand-new prescription. Your new Arkansas pharmacy cannot call your previous pharmacy to transfer the remaining fills. Contact your prescriber directly and allow two to five business days for the new prescription to be processed.

503A compounding pharmacies in Arkansas

A licensed 503A compounding pharmacy in Arkansas may prepare customized lisdexamfetamine formulations, such as alternative capsule strengths or oral solutions, for patients with documented medical need for a non-commercially available form. The compound must be made pursuant to a valid patient-specific prescription. Arkansas 503A pharmacies are licensed by the Arkansas State Board of Pharmacy and must comply with USP <795> and USP <797> standards where applicable.

503A pharmacies cannot ship compounded Schedule II substances across state lines to Arkansas patients; the compounding and dispensing must occur within Arkansas. Confirm a pharmacy's 503A license status at the Arkansas State Board of Pharmacy before filling.

Clinical Evidence Supporting Vyvanse

Understanding the evidence base helps you have a more productive conversation with your prescriber and strengthens any PA appeal.

ADHD evidence

Wigal et al. (2017) conducted a placebo-controlled crossover study in adults and found that lisdexamfetamine produced statistically significant improvements on the Permanent Product Measure of Performance (PERMP) compared with placebo (P<0.001), with effect sizes consistent with earlier key trials. PubMed PMID 26861148.

The key Phase 3 ADHD trial program for Vyvanse showed that lisdexamfetamine 30 mg to 70 mg reduced ADHD Rating Scale IV scores by an average of 16.2 to 18.6 points from baseline versus 8.8 points for placebo across the adult population studied. Responder rates (defined as a 30% or greater reduction in symptom score) reached approximately 60% at the 70 mg dose in that program.

Binge eating disorder evidence

The two registrational Phase 3 BED trials (SPD489-343 and SPD489-344) enrolled a combined 724 adults with moderate-to-severe BED. Patients receiving lisdexamfetamine 50 mg or 70 mg experienced a mean of 3.87 fewer binge eating days per week versus 1.28 fewer days with placebo. The FDA granted approval for the BED indication in January 2015 based on these data. The full trial results are summarized in the FDA medical review.

The American Psychiatric Association's Practice Guideline for BED notes that pharmacological treatment, including lisdexamfetamine, may be appropriate when structured behavioral intervention alone has not produced adequate reduction in binge frequency. Dosing should be titrated based on tolerability, and cardiovascular parameters should be monitored throughout treatment.

Monitoring and Follow-Up After Starting Vyvanse in Arkansas

Your prescriber should schedule a follow-up appointment two to four weeks after initiating Vyvanse to assess response and tolerability. At each visit, expect review of:

• Blood pressure and pulse (stimulants can raise systolic BP by 2 to 4 mmHg on average and heart rate by 3 to 6 bpm)
• Weight (particularly important in children and in patients being treated for BED)
• Sleep quality (insomnia is the most frequently reported adverse event, occurring in roughly 19% of adults in the Phase 3 ADHD trials)
• Appetite and nutrition (decreased appetite occurs in approximately 26% of adults)
• Mood, anxiety, and any signs of mania or psychosis
• Substance use (continued monitoring is standard for Schedule II prescriptions)

Because Arkansas requires a new prescription each calendar month, many prescribers will schedule monthly 15-minute check-in appointments to co-ordinate refill prescriptions. Some telehealth platforms automate this via asynchronous check-ins with a follow-up prescription sent electronically if no concerns arise.

Special Populations in Arkansas

Pediatric patients (ages 6 to 17)

The FDA label approves lisdexamfetamine for ADHD in children aged 6 and older. Arkansas Medicaid covers Vyvanse for pediatric ADHD under similar PA criteria as adults. Growth monitoring (height and weight percentile tracking at each visit) is standard because stimulants may reduce growth velocity in some children. The American Academy of Pediatrics 2019 ADHD guidelines recommend periodic medication holidays (typically summer breaks from school) to assess continued need and allow weight recovery if growth is affected.

Pregnant and postpartum patients

Vyvanse is FDA Pregnancy Category not applicable under current labeling (post-2015 PLLR framework), but preclinical data show risk. The drug should be used during pregnancy only if the potential benefit clearly justifies the potential risk to the fetus. Arkansas providers are expected to counsel patients of reproductive age about contraception and the risks of in utero amphetamine exposure, including preterm birth and neonatal withdrawal. Neonates exposed to amphetamines near delivery may show irritability, feeding difficulty, and dysphoria.

Patients with prior substance use disorder

A personal history of stimulant misuse or alcohol use disorder is not an absolute contraindication to Vyvanse, but it does require more careful risk-benefit analysis. The prodrug design of lisdexamfetamine (enzymatic cleavage in the gut releases d-amphetamine) reduces but does not eliminate abuse potential. Arkansas prescribers treating patients with SUD histories often require more frequent urine drug screens, shorter prescription durations (7 to 14 days), and co-ordination with addiction medicine or behavioral health specialists.

Cost and Savings Options in Arkansas

The cash price of Vyvanse 30 mg (30 capsules) ranges from approximately $380 to $440 at Arkansas retail pharmacies without insurance as of early 2025. Generic lisdexamfetamine became available in the United States in 2023 after Takeda's exclusivity expired and typically costs $80 to $140 for a 30-day supply at Arkansas pharmacies, though availability remains inconsistent due to the same manufacturing shortage affecting the brand.

GoodRx and similar discount programs can reduce the generic cost further. Mark Cuban's Cost Plus Drugs listed generic lisdexamfetamine at approximately $76 for 30 capsules (30 mg) when stock is available, with shipping to Arkansas.

Takeda's patient assistance program (TAP) provides free Vyvanse to qualifying patients who meet income thresholds. Contact Takeda directly or ask your prescriber's office to submit a PAP application on your behalf if you are uninsured or underinsured.